MA
IBRX icon

Mutual Advisors’s ImmunityBio IBRX Stock Holding History

Mutual Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
32,697
+1,145
+4% +$8.67K 0.01% 1191
2026
Q1 		$242K Buy
31,552
+1,352
+4% +$9.26K 0.01% 1206
2025
Q4 		$59.8K Buy
30,200
+2,500
+9% +$5.66K ﹤0.01% 1283
2025
Q3 		$66.2K Buy
27,700
+11,500
+71% +$29.6K ﹤0.01% 1268
2025
Q2 		$46.3K Hold
16,200
– – ﹤0.01% 1165
2025
Q1 		$42.3K Hold
16,200
– – ﹤0.01% 1072
2024
Q4 		$49.2K Buy
+16,200
New +$67.5K ﹤0.01% 1061

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mutual Advisors's IBRX Position: Q2 2026 in Review

Mutual Advisors increased its ImmunityBio (IBRX) stake by 3.6% in Q2 2026, buying an estimated $8.67K and bringing the position to 32,697 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #1191.

Mutual Advisors first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Mutual Advisors held 32,697 shares of ImmunityBio worth $286K as of Q2 2026.
  • Mutual Advisors bought 1,145 ImmunityBio shares in Q2 2026, an estimated $8.67K.
  • ImmunityBio made up 0.01% of Mutual Advisors's portfolio in Q2 2026, its #1191 holding.
  • Mutual Advisors first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Mutual Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.